Loading...
•
Dec 31, 2022
EyePoint Pharmaceuticals Q4 2022 Earnings Report
EyePoint Pharmaceuticals reported financial results for Q4 2022 and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported total net revenue of $10.5 million for the quarter ended December 31, 2022, compared to $11.5 million for the quarter ended December 31, 2021. Net loss was $43.5 million, or ($1.16) per share, compared to a net loss of $19.4 million, or ($.59) per share, for the prior year period.
Net product revenues for Full Year 2022 of $39.9 million, a 13.0% increase versus Full Year 2021 of $35.3 million
YUTIQ net product revenue was $9.0 million in Q4 2022, a 55% increase compared to Q4 2021.
Customer demand for YUTIQ was approximately 980 units in Q4 2022 compared to approximately 890 units for 3Q 2022, a 10% increase.
$144.6M of cash and investments at December 31, 2022 with cash runway projected into 2H 2024
Revenue by Segment
Forward Guidance
We expect the cash, cash equivalents and investments on hand on December 31, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...